Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655170 · ClinicalTrials.gov registry record · Phase 4
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
A Phase 4 study, sponsored by University of Tennessee Graduate School of Medicine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT04655170 is a Phase 4 study that is actively recruiting participants, run by University of Tennessee Graduate School of Medicine. The registered enrollment target is 60 participants.
The verdict
NCT04655170, a Phase 4 study, is actively recruiting participants, sponsored by University of Tennessee Graduate School of Medicine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
Interventions
- DRUG Revefenacin (YUPELRI) & Formoterol (Perforomist)
- DRUG Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04655170
The ClinicalTrials.gov registry entry for NCT04655170 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee Graduate School of Medicine, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Revefenacin (YUPELRI) & Formoterol (Perforomist) is the first listed.
NCT04655170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04655170 about?
NCT04655170 is a clinical study titled "Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD". The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
What is the current status of trial NCT04655170?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2020-12-09. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT04655170?
The interventions under investigation include: Revefenacin (YUPELRI) & Formoterol (Perforomist) (DRUG), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) (DRUG).
Who is sponsoring clinical trial NCT04655170?
This trial is sponsored by University of Tennessee Graduate School of Medicine, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.